GCAR1

Phase 1Cell therapy

AAHS Cancer Control Alberta

GCAR1 is one of 5 biologic programs targeting Alveolar Soft Part Sarcoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alveolar Soft Part SarcomaActive, not recruiting

Alveolar Soft Part SarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Alveolar Soft Part Sarcoma

#DrugCompanyPhaseTrials

DTIC-Dome

Bayer

Phase 3

1 2

Tecentriq

Roche

Phase 2

2 3

Xpovio

KKaryopharm Therapeutics Inc

Phase 2

1 4

AL3818

AAdvenchen Laboratories, LLC

Phase 3

1 5

GCAR1

AAHS Cancer Control Alberta

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Alveolar Soft Part Sarcoma

NCT07104682

Q1 2028

Phase 1Active, not recruiting

Alveolar Soft Part Sarcoma

NCT06789081

Q1 2030

Phase 1Active, not recruiting

Alveolar Soft Part Sarcoma

NCT06813417

Q3 2033

Phase 1Recruiting

Alveolar Soft Part Sarcoma

NCT07297667

Clinical

Trials by Indication[1]

Alveolar Soft Part Sarcoma5 trials

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma

Completed·AAHS Cancer Control Alberta·Phase 1·NCT06827886·1 enrolled

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)

Active, not recruiting·AAHS Cancer Control Alberta·Phase 1·NCT06789081·1 enrolled

CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma

Active, not recruiting·UUniversity of Calgary·Phase 1·NCT06813417·1 enrolled

Show 2 more trials

A Phase I Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Participants With Selected Relapsed/Refractory GPNMB-Expressing Solid Tumours

Recruiting·CCanadian Cancer Trials Group·Phase 1·NCT07297667·30 enrolled

An Open Label Individual Patient Study Investigating the Safety and Efficacy of GCAR1 in a Patient With Metastatic Relapsed Alveolar Soft Part Sarcoma

Active, not recruiting·UUniversity of Calgary·Phase 1·NCT07104682·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GCAR1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GCAR1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GCAR1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AHS Cancer Control Alberta company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: AAHS Cancer Control Alberta

GCAR1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Q1 2030

Q3 2033

Trials by Indication[1]

Alveolar Soft Part Sarcoma5 trials

References

Drug Info

Quick Facts

Related News